This study will compare three versions of the Pericapsular Nerve Group (PENG) block in adults aged 65 years and older who are undergoing hip surgery. The PENG block is a regional anesthesia technique used to reduce pain around the hip joint and may improve early recovery after surgery. All patients in the study will receive the PENG block using 20 mL of 0.2% ropivacaine. They will then be randomly assigned to one of three groups: Group 1: PENG block using ropivacaine only (no additional medications). Group 2: PENG block using ropivacaine with 4 mg of dexamethasone injected near the nerves. Group 3: PENG block using ropivacaine with 25 micrograms of dexmedetomidine injected near the nerves. Dexamethasone and dexmedetomidine are medications that may increase the duration and quality of regional anesthesia. It is not known whether adding one of these medications provides longer-lasting or better pain relief compared to using ropivacaine alone. The main purpose of this study is to determine whether the addition of dexamethasone or dexmedetomidine improves the effectiveness of the PENG block in relieving pain after hip surgery. The study will evaluate pain levels, opioid consumption, time to first rescue pain medication, need for additional analgesia, and recovery outcomes. Safety, side effects, and any block-related complications will also be monitored. We hypothesize that adding either perineural dexamethasone or dexmedetomidine will result in longer and more effective pain relief compared with the standard PENG block without an adjuvant. This research may help identify the most effective form of the PENG block for older adults undergoing hip surgery and contribute to improved pain management, reduced opioid use, and better postoperative recovery.
Hip surgery in older adults is frequently associated with significant postoperative pain, delayed mobilization, and increased opioid requirements. Poor pain control in this population can lead to complications such as delirium, prolonged hospitalization, reduced physical function, and slower rehabilitation. Effective regional anesthesia may improve safety and recovery after hip surgery. The Pericapsular Nerve Group (PENG) block is a relatively new regional anesthesia technique designed to target the sensory innervation of the hip joint while preserving motor function. This motor-sparing feature may allow earlier mobilization and reduce the negative effects of immobilization in older patients. Ropivacaine is the standard local anesthetic commonly used in peripheral nerve blocks. Small doses of adjuvant medications such as dexamethasone or dexmedetomidine may prolong the duration of analgesia and improve the quality of pain control. However, it remains unclear whether the addition of these medications provides any clinically meaningful benefit when used with the PENG block in older adults. There is also limited evidence directly comparing different adjuvants to a standard PENG block without additional medication. This randomized controlled trial will compare three variants of the PENG block in adults aged 65 years and older undergoing hip surgery. All participants will receive a PENG block with 20 mL of 0.2% ropivacaine. They will then be randomly assigned to one of three groups: Standard PENG block with ropivacaine alone (no adjuvant). PENG block with 4 mg of perineural dexamethasone. PENG block with 25 micrograms of perineural dexmedetomidine. All patients will receive standard perioperative care and multimodal analgesia. The study will assess pain scores, time to first rescue analgesia, total opioid consumption, functional mobility, incidence of postoperative nausea and vomiting, block duration, motor function, and complications. Safety will also be monitored, including block-related and neurological adverse events. The primary objective of this study is to determine whether perineural dexamethasone or dexmedetomidine improves postoperative analgesia compared with a standard PENG block without adjuvant. We hypothesize that both adjuvants may prolong analgesia and reduce opioid requirements, but their effectiveness and safety profile may differ. This study aims to provide evidence that can help guide anesthesiologists in selecting the optimal variant of the PENG block for older adults undergoing hip surgery, intending to improve postoperative pain control, support early rehabilitation, and reducing complications associated with opioid use and delayed mobilization.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
120
20 mL of 0.2% ropivacaine administered perineurally as part of the PENG block. No perineural or intravenous adjuvant drugs will be used in this arm.
4 mg of dexamethasone administered perineurally together with 20 mL of 0.2% ropivacaine for the PENG block. No intravenous dexamethasone will be administered.
25 micrograms of dexmedetomidine administered perineurally together with 20 mL of 0.2% ropivacaine for the PENG block. No intravenous dexamethasone will be administered.
Poznan University of Medical Sciences
Poznan, Poland
Time to First Rescue Analgesia
Time (in hours) from completion of the PENG block to the first administration of a rescue analgesic (opioid or non-opioid) given for pain intensity ≥4 on the 0-10 Numerical Rating Scale (NRS).
Time frame: Within 48 hours after surgery.
Pain Intensity at Rest (NRS 0-10)
Pain intensity at rest measured using the 0-10 Numerical Rating Scale (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups across predefined time points.
Time frame: 4 hours after surgery.
Pain Intensity at Rest (NRS 0-10)
ain intensity at rest measured using the 0-10 Numerical Rating Scale (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups across predefined time points.
Time frame: 8 hours after surgery.
Pain Intensity at Rest (NRS 0-10)
ain intensity at rest measured using the 0-10 Numerical Rating Scale (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups across predefined time points.
Time frame: 12 hours after surgery.
Pain Intensity at Rest (NRS 0-10)
ain intensity at rest measured using the 0-10 Numerical Rating Scale (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups across predefined time points.
Time frame: 24 hours after surgery.
Pain Intensity at Rest (NRS 0-10)
ain intensity at rest measured using the 0-10 Numerical Rating Scale (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups across predefined time points.
Time frame: 48 hours after surgery.
Pain Intensity During Movement (NRS 0-10)
Pain intensity during standardized hip movement (e.g., flexion or assisted mobilization) measured using the 0-10 Numerical Rating Scale.
Time frame: 4 hours after surgery.
Pain Intensity During Movement (NRS 0-10)
Pain intensity during standardized hip movement (e.g., flexion or assisted mobilization) measured using the 0-10 Numerical Rating Scale.
Time frame: 8 hours after surgery.
Pain Intensity During Movement (NRS 0-10)
Pain intensity during standardized hip movement (e.g., flexion or assisted mobilization) measured using the 0-10 Numerical Rating Scale.
Time frame: 12 hours after surgery.
Pain Intensity During Movement (NRS 0-10)
Pain intensity during standardized hip movement (e.g., flexion or assisted mobilization) measured using the 0-10 Numerical Rating Scale.
Time frame: 24 hours after surgery.
Pain Intensity During Movement (NRS 0-10)
Pain intensity during standardized hip movement (e.g., flexion or assisted mobilization) measured using the 0-10 Numerical Rating Scale.
Time frame: 48 hours after surgery.
Total Opioid Consumption
Cumulative dose of opioids converted to oral morphine milligram equivalents (MME).
Time frame: 0-24 hours and 0-48 hours after surgery.
Motor Function Preservation (Quadriceps Strength, MRC Scale)
Quadriceps muscle strength will be assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the applied regional anesthesia techniques.
Time frame: 4 hours after surgery.
Motor Function Preservation (Quadriceps Strength, MRC Scale)
Quadriceps muscle strength will be assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the applied regional anesthesia techniques.
Time frame: 8 hours after surgery.
Motor Function Preservation (Quadriceps Strength, MRC Scale)
Quadriceps muscle strength will be assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the applied regional anesthesia techniques.
Time frame: 12 hours after surgery.
Motor Function Preservation (Quadriceps Strength, MRC Scale)
Quadriceps muscle strength will be assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the applied regional anesthesia techniques.
Time frame: 24 hours after surgery.
Motor Function Preservation (Quadriceps Strength, MRC Scale)
Quadriceps muscle strength will be assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the applied regional anesthesia techniques.
Time frame: 48 hours after surgery.
Incidence of Postoperative Nausea and Vomiting (PONV)
Presence of nausea or vomiting requiring antiemetic therapy. Proportion of patients with at least one episode will be recorded.
Time frame: 0-48 hours after surgery.
Hemodynamic Adverse Events
Incidence of hypotension (systolic BP \<90 mmHg or \>30% decrease from baseline) and bradycardia (HR \<50/min) requiring treatment.
Time frame: From block placement until 24 hours after surgery.
Block-Related Adverse Events, Including Neurological Complications
Incidence of complications related to the PENG block or perineural adjuvants, including prolonged sensory or motor deficit, nerve injury (evaluated in outpatient clinic if required), hematoma, infection at the injection site, persistent weakness, or local anesthetic systemic toxicity.
Time frame: From block placement until 30 days after surgery.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.